Jens Kemp - 26 Feb 2026 Form 4 Insider Report for Axogen, Inc. (AXGN)

Role: Chief Marketing Officer
Signature: Marc Began, as attorney-in-fact for Jens Kemp
Issuer symbol: AXGN
Transactions as of: 26 Feb 2026
Net transactions value: -$582,185
Form type: 4
Filing time: 02 Mar 2026, 18:16:56 UTC
Previous filing: 10 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kemp Jens	Chief Marketing Officer	13631 PROGRESS BLVD.,, SUITE 400, ALACHUA	Marc Began, as attorney-in-fact for Jens Kemp	02 Mar 2026	0002007485

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AXGN	Common Stock	Award	$0	+50,670	+115%	$0.000000	94,817	26 Feb 2026	Direct	F1, F2, F3
transaction	AXGN	Common Stock	Tax liability	$491,707	-15,414	-16%	$31.90	79,403	26 Feb 2026	Direct	F4
transaction	AXGN	Common Stock	Tax liability	$90,479	-2,952	-3.7%	$30.65	76,451	01 Mar 2026	Direct	F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AXGN	Restricted Stock Units	Award	$0	+23,000		$0.000000	23,000	26 Feb 2026	Common Stock	23,000		Direct	F6, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This reflects the number of shares that became vested as of February 26, 2026, upon the attainment and certification of certain performance criteria.
F2	The previous Form 4 filed by the Reporting Person overstated the number of shares beneficially owned by the Reporting Person by 4,003 shares of Common Stock. The amount reported herein has been corrected.
F3	Includes 2,120 shares acquired under the Axogen Employee Stock Purchase Plan on December 31, 2025.
F4	No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of performance stock units ("PSUs").
F5	No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of restricted stock units ("RSUs").
F6	Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F7	All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.